Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01906359
Other study ID # A005/11
Secondary ID NMRR-12-146-1136
Status Completed
Phase N/A
First received July 11, 2013
Last updated October 9, 2015
Start date September 2012
Est. completion date March 2014

Study information

Verified date October 2015
Source Malaysia Palm Oil Board
Contact n/a
Is FDA regulated No
Health authority Malaysia: Ministry of Health
Study type Interventional

Clinical Trial Summary

Type 2 diabetes mellitus (T2DM) is a chronic disorder determined by lifestyle and genes. It is associated with chronic hyperglycaemia along with other metabolic abnormalities. It is also one of the risk factors for cardiovascular disease (CVD). This disease is due to insulin resistance and/or deficiency as well as increased hepatic glucose output. According to the Third National Health and Morbidity Survey (3rd NHMS), the prevalence of T2DM for adults aged 30 years and above is 14.9%, increased by almost 80% from 1996 to 2006. Dietary composition may affect insulin sensitivity, postprandial triacylglycerol concentration and the risk of T2DM. The role of dietary fats in T2DM is of particular interest and has been clinically studied for many decades. The type of fat we ingest every day consists of different types of fatty acids and different degree of saturation, which in turn influence glucose metabolism by altering cell membrane function, enzyme activity, insulin signalling and gene expression. Previous studies demonstrated that interesterification of dietary fat alter postprandial lipaemia. Saturated fat such as palm olein has been reported to display lower postprandial lipaemia after interesterification. Changing the structure of triacylglycerol (TAG) alters the physical properties of dietary fat which affects digestibility, metabolism and atherogenicity. A recent study conducted by Sanders and co-workers demonstrated reduced levels of plasma glucose-dependent insulinotropic polypeptide (GIP) following both the lard and interesterified palm olein (IPO) compared with the palm olein (PO) and high oleic sunflower oil (HOS) diets in healthy subjects. The GIP and glucagon-like peptide-1 (GLP-1) are major players in the modulation of postprandial insulin secretion by the pancreas. Although GIP secretion in response to meals is normal in patients with Type 2 diabetes mellitus (T2DM), GIP induced secretion of insulin is defective in diabetes. This is observed to be predominantly a defective stimulation of the late phase of insulin response (20-120 minutes). The effect of IPO on GIP may be exaggerated in T2DM patients with impaired insulin sensitivity. Hence, IPO may change the concentrations of gut hormones, postprandial lipaemia, insulinaemic response and CVD related haemostatic markers.


Description:

Subjects aged between 30 and 60 years old (male and female) with Type 2 diabetes mellitus (T2DM) will be recruited for this study. A randomized, crossover, double-blind study design will be carried out to investigate the acute effects of high fat meals prepared using palm olein (PO), chemically interesterified palm olein (IPO) and high oleic sunflower oil (HOS) (control) on study subjects with T2DM. Study subjects will have to undergo three postprandial challenges, separated by at least one week interval. Fasting blood sample and duplicate baseline blood samples will be taken in the morning of postprandial day. After that, subjects will be asked to consume a test meal consisting a high fat muffin baked using the aforementioned oils and a milkshake within 10 minutes. After meal, venous blood samples will be taken at time-points 15, 30, 60, 90, 120 min, 3 h, 4 h, 5 h, 6 h and post-heparin plasma 5 min and 15 min for analysis. Pulse wave analysis will be conducted to evaluate central blood pressure and arterial stiffness. Meal appreciation will be assessed by utilising visual analogue scale (VAS) before eating, after eating and at each time-point.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date March 2014
Est. primary completion date July 2013
Accepts healthy volunteers No
Gender Both
Age group 30 Years to 60 Years
Eligibility Inclusion Criteria:

1. Mild T2DM individuals not planned for medical intervention

- 7.0 mmol/L = fasting glucose = 11.1 mmol/L

- 6.5% = HbA1c = 9.0%

- Not using antihypertensive, lipid lowering, insulin/glucose modulating medication

2. Mild T2DM individuals currently on medical intervention

- Fasting glucose = 11.1 mmol/L

- HbA1c = 9.0%

- Using antihypertensive, lipid lowering or glucose modulating medication

3. Malaysian male or female with T2DM aged between 30 to 60 years old

4. Not using insulin

5. Not having any complications of diabetes

6. No medical history of myocardial infarction, angina, thrombosis, stroke or cancer

7. Haemoglobin levels for females = 11.5 gm/dl and males = 12.5 gm/dl

8. Serum ferritin > 15 µg/l at commencement of study

Exclusion Criteria:

1. Medical history of myocardial infarction, angina, thrombosis, stroke or cancer

2. Underweight (BMI < 18.5 kg/m²)

3. Using insulin

4. Total cholesterol > 7.0 mmol/L

5. Abnormal liver function, renal function and haematology

6. Hypersensitive towards heparin

7. Gastric or lactose intolerance

8. Smoker

9. Pregnancy and lactating

10. Taking alcohol

11. Taking alcohol

12. Haemoglobin levels for females = 11.5 gm/dl and males = 12.5 gm/dl

13. Serum ferritin < 15 µg/l at commencement of study

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Intervention

Other:
Native palm olein (IV56)
Test meal consists of a high fat muffin (containing 50 g native palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
Chemically interesterified palm olein (IV56)
Test meal consists of a high fat muffin (containing 50 g chemically interesterified palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
High oleic sunflower oil
Test meal consists of a high fat muffin (containing 50 g high oleic sunflower oil) and a cup of milkshake, to be taken as breakfast for each postprandial study day.

Locations

Country Name City State
Malaysia Hulu Langat District Health Office Kajang Selangor
Malaysia Malaysian Palm Oil Board (MPOB) Kajang Selangor
Malaysia Sepang District Health Office Sepang Selangor
Malaysia Universiti Putra Malaysia Serdang Selangor
Malaysia Selangor State Health Office Shah Alam Selangor

Sponsors (3)

Lead Sponsor Collaborator
Malaysia Palm Oil Board Ministry of Health, Malaysia, Universiti Putra Malaysia

Country where clinical trial is conducted

Malaysia, 

Outcome

Type Measure Description Time frame Safety issue
Primary 6-hour postprandial changes from fasting in glucose-dependent insulinotropic polypeptide (GIP) To determine the postprandial changes of GIP. 0, 15, 30, 60, 90, 120 min, 3, 4, 5, 6 hour No
Secondary 6-hour postprandial changes from fasting in gut hormones To determine the postprandial changes of ghrelin, glucagon-like peptide-1 (GLP-1), peptide YY (PYY) and cholecystokinin (CCK). 0, 15, 30, 60, 90, 120 min, 3, 4, 5, 6 h No
Secondary 6-hour postprandial changes from fasting in insulinaemic response To determine the postprandial changes of glucose, insulin, C-peptide and non-esterified fatty acid (NEFA) 0, 15, 30, 60, 90, 120 min, 3, 4, 5, 6 hour No
Secondary 6-hour postprandial changes from fasting in lipaemia To determine the postprandial changes of triacylglycerol (TAG) and apolipoprotein B48 (apoB48).
To compare lipoprotein lipase (LPL) activity, chylomicron fatty acid composition and plasma fatty acid (PFA) composition across meals.
0, 1, 2, 3, 4, 5, 6 hour for TAG and apoB48; 6 hour postheparin for LPL; pooled 3, 4, 5 hour for chylomicron and PFA No
Secondary 6-hour postprandial changes from fasting in haemostatic response To determine the postprandial changes of factor FVII activation (FVIIa), plasminogen activator inhibitor-1 (PAI-1)and D-dimer.
To compare pulse wave analysis (PWA) across meals.
0, 2, 4, 6 hour for FVIIa, PAI-1 and D-dimer; 0, 4 hour for PWA No
Secondary 6-hour changes from fasting hunger rating using visual analogue scale (VAS) To determine the changes in hunger rating and food satiety 0, 15, 30, 60, 90, 120 min, 3, 4, 5, 6 hour No
See also
  Status Clinical Trial Phase
Completed NCT02771093 - An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus Phase 4
Completed NCT02545842 - Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL) Phase 4
Recruiting NCT03436212 - Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump. N/A
Completed NCT03244800 - A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. Phase 2
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Withdrawn NCT02769091 - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes Phase 2
Recruiting NCT06065540 - A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Phase 3
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT04091373 - A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide Phase 1
Completed NCT03296800 - Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects Phase 1
Recruiting NCT06212778 - Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
Completed NCT05979519 - Fresh Carts for Mom's to Improve Food Security and Glucose Management N/A
Recruiting NCT05579314 - XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Terminated NCT03684642 - Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Phase 3
Completed NCT03248401 - Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes Phase 4
Completed NCT03644134 - A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns N/A
Completed NCT05295160 - Fasting-Associated Immune-metabolic Remission of Diabetes N/A
Completed NCT02836873 - Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment Phase 3
Completed NCT02252224 - Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance